Advertisement
MRNA vs NVAX
Which Stock Would AI Choose? Moderna (MRNA) vs. Novavax (NVAX) Stock Comparison
Key Takeaways
- MRNA has delivered a dramatic relative performance run in recent months, driven by positive late-stage data for its personalized cancer vaccine developed with Merck.
- NVAX has transitioned toward a leaner, partner-led model centered on its Matrix-M adjuvant and licensing agreements with Sanofi and Pfizer.
- The two companies represent very different market positions: Moderna is a diversified mRNA platform with a large market capitalization, while Novavax is a much smaller, asset-licensing biotech.
- Both stocks carry elevated valuation risk after sharp rallies, but the catalysts and investor narratives behind each are distinct.
- Recent market activity has favored Moderna on momentum and breadth of pipeline, while Novavax offers exposure to royalty and licensing economics with lower operating costs.
Introduction
Investors tracking the vaccine and biotechnology space frequently weigh MRNA against NVAX, two companies that rose to prominence during the COVID-19 era but have since diverged sharply. This stock comparison is relevant for traders and investors seeking to understand how a diversified messenger RNA (mRNA) platform company contrasts with a smaller, partnership-driven vaccine developer. While both operate in the infectious-disease space, their business models, growth drivers, and risk profiles differ considerably. Understanding their relative performance and market positioning can help investors evaluate which profile aligns with their own time horizon and risk tolerance.
MRNA Overview and Recent Performance
Moderna is a Cambridge, Massachusetts-based biotechnology company built around its mRNA platform, which spans infectious-disease vaccines, oncology, and rare diseases. Its commercial portfolio includes COVID-19 vaccines and an RSV vaccine, with a combination COVID-19 and influenza shot recently approved in the European Union. Recent weeks have been defined by a sharp re-rating after Moderna and Merck announced that a Phase 3 trial of the personalized cancer vaccine intismeran autogene, combined with Keytruda, met its primary goal in high-risk melanoma patients. The stock subsequently climbed to multi-year highs, with a market capitalization reaching tens of billions of dollars and a pending return to the Nasdaq-100 index.
Sentiment has been reinforced by strong international sales in recent quarterly results and progress on its standalone flu candidate, which has a U.S. regulatory decision pending. However, the rally has also drawn caution from analysts who argue the valuation now prices in oncology success well beyond current evidence. This tension between pipeline momentum and valuation has made MRNA one of the more volatile large-cap biotech names in the current market environment.
NVAX Overview and Recent Performance
Novavax is a Gaithersburg, Maryland-based biotechnology company focused on vaccines for serious infectious diseases. Its core asset is a recombinant protein-based COVID-19 vaccine, Nuvaxovid, enhanced by its proprietary Matrix-M adjuvant, an ingredient designed to strengthen the immune response. In recent years, Novavax has shifted away from direct commercial operations toward a partner-led strategy, licensing Nuvaxovid commercialization to Sanofi and licensing Matrix-M technology to partners including Pfizer across more than 30 fields spanning infectious disease and oncology.
Recent market activity has been more moderate than Moderna's, though Novavax shares have also gained in 2026, supported by better-than-expected quarterly results, cost reductions, and licensing momentum. The company's revenue mix is increasingly weighted toward partner-related royalties, milestones, and supply sales rather than direct product sales, which have declined sharply. Novavax carries a market capitalization in the low single-digit billions, and its share price remains sensitive to sector-wide vaccine sentiment, as illustrated by a brief spike and pullback tied to infectious-disease headlines. Analysts remain divided, with some highlighting licensing upside and others citing persistent unprofitability and financial-strength concerns.
Trending AI Robots
For traders seeking a systematic approach to names like MRNA and NVAX, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and statistical profile. Because only a subset of these bots is well suited to prevailing market conditions at any given moment, the Trending AI Robots section highlights the ones currently demonstrating the strongest alignment with the market. Exploring this page can help investors see how quantitative, rules-based systems are positioning across both momentum and mean-reversion approaches, including within the volatile biotechnology sector.
Head-to-Head Comparison
The clearest contrast between these two stocks lies in their business models. Moderna operates a broad, diversified platform with multiple marketed products and a pipeline spanning respiratory vaccines and personalized oncology, giving it multiple potential revenue pillars but also substantial research and development spending. Novavax, by comparison, is a leaner operation focused on monetizing its adjuvant technology and vaccine franchise through partners, which lowers its cost base but leaves its growth tied to counterparty execution and milestone conversion.
On growth drivers, Moderna's near-term narrative is dominated by the oncology opportunity and regulatory milestones, while Novavax's hinges on licensing agreements, royalty streams, and cost discipline. Recent momentum strongly favors Moderna, which has outperformed the broader sector by a wide margin, whereas Novavax has posted more modest gains. Risk factors also differ: Moderna faces elevated valuation expectations and binary clinical catalysts, while Novavax contends with declining direct product sales, financial-strength constraints, and a smaller liquidity buffer relative to its larger peer.
Sector exposure is another differentiator. Both are sensitive to infectious-disease headlines, but Moderna's diversified pipeline and larger scale give it a different risk-reward profile than Novavax's more concentrated, licensing-driven model. Market sentiment around MRNA has swung between enthusiasm and valuation caution, while NVAX sentiment reflects a more guarded view of its transition to a partner-dependent business.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative strength, and the breadth of near-term catalysts, Tickeron's AI would likely favor MRNA in the current environment. The stock's sustained upward momentum, multiple pipeline catalysts, and improving revenue trajectory provide a stronger quantitative setup than the more gradual, partner-dependent progress at NVAX. That said, Moderna's elevated valuation and binary data events introduce meaningful downside volatility, which automated systems would typically weight carefully. The relative positioning therefore leans toward Moderna on momentum and catalyst breadth, while Novavax may appeal to models emphasizing stability, lower operating costs, and licensing-based revenue rather than high-growth momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNA is a Buy and NVAX is a Buy.
MRNA in +8.34% Uptrend, rising for three consecutive days on October 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MRNA advanced for three days, in 213 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Aroon Indicator entered an Uptrend today. In 101 of 132 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for MRNA moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.742) is normal, around the industry mean (3.037). P/E Ratio (-24.919) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NVAX's Stochastic Oscillator is remaining in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 50-day moving average for NVAX moved above the 200-day moving average on September 24, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in 183 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 95 of 117 cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVAX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 20 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVAX as a result. In 72 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
NVAX moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NVAX broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.130) is normal, around the industry mean (3.037). P/E Ratio (-6.144) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (3.759) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MRNA | NVAX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 79 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 1 | 43 | |
P/E GROWTH RATING 1..100 | 99 | 99 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVAX's Valuation (10) in the Biotechnology industry is in the same range as MRNA (12). This means that NVAX’s stock grew similarly to MRNA’s over the last 12 months.
NVAX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MRNA (100). This means that NVAX’s stock grew similarly to MRNA’s over the last 12 months.
MRNA's SMR Rating (97) in the Biotechnology industry is in the same range as NVAX (100). This means that MRNA’s stock grew similarly to NVAX’s over the last 12 months.
MRNA's Price Growth Rating (1) in the Biotechnology industry is somewhat better than the same rating for NVAX (43). This means that MRNA’s stock grew somewhat faster than NVAX’s over the last 12 months.
MRNA's P/E Growth Rating (99) in the Biotechnology industry is in the same range as NVAX (99). This means that MRNA’s stock grew similarly to NVAX’s over the last 12 months.
| MRNA | NVAX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 87% |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 85% |
| Advances ODDS (%) | 7 days ago 78% | 29 days ago 79% |
| Declines ODDS (%) | 1 day ago 87% | 1 day ago 87% |
| BollingerBands ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 77% | 1 day ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRNA’s FA Score shows that 2 FA rating(s) are green while NVAX’s FA Score has 1 green FA rating(s).
- MRNA’s FA Score: 2 green, 3 red.
- NVAX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRNA’s TA Score shows that 3 TA indicator(s) are bullish while NVAX’s TA Score has 4 bullish TA indicator(s).
- MRNA’s TA Score: 3 bullish, 5 bearish.
- NVAX’s TA Score: 4 bullish, 6 bearish.
Price Growth
MRNA (@Biotechnology) experienced а -12.36% price change this week, while NVAX (@Biotechnology) price change was -13.12% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -15.42%, and the average quarterly price growth was -14.11%.
Reported Earning Dates
MRNA is expected to report earnings on Nov 06, 2026.
NVAX is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-0.45% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement